Oncology drugs are medications that are used to treat cancer. These drugs work by targeting and killing cancer cells or slowing down their growth and spread. The oncology drug market in China is a significant and rapidly growing market, driven by the increasing incidence of cancer in the country and the growing demand for effective cancer treatments. 最新の研究によると, the oncology drug market in China is poised to grow by USD 41.0 billion during 2023-2029, CAGR で進歩 12.46% 予測期間中. One of the key drivers of growth in the oncology drug market in China is the increasing incidence of cancer in the country. According to the National Cancer Center of China, the number of new cancer cases in China is expected to reach 4.5 百万までに 2025. This has led to a growing demand for effective cancer treatments and has created opportunities for pharmaceutical companies to develop and market new oncology drugs. Another factor driving growth in the oncology drug market in China is the increasing government support for cancer research and treatment. The Chinese government has launched several initiatives to improve cancer prevention, 診断, and treatment, and has increased funding for cancer research and development. In addition, the rise of precision medicine and targeted therapies has led to the development of new oncology drugs that are more effective and have fewer side effects compared to traditional chemotherapy. These drugs are designed to target specific cancer cells or genetic mutations, and are personalized to each patient’s unique cancer profile.

この業界レポートは中国市場の市場予測を提供します。, 続いてタイプの詳細な分析, and product. The China market data on oncology drug can be segmented by type: breast, colorectum, 肝臓, 肺癌, stomach, thyroid, その他. Oncology drug market is further segmented by product: chemotherapy drugs, immunotherapy drugs, targeted drugs. Chemotherapy drugs was the highest contributor to the oncology drug market in China. 今後, the immunotherapy drugs segment is projected to witness the highest CAGR during the forecast period.

The China oncology drug market is highly competitive. The oncology drug market is dominated by key players, which are AstraZeneca plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Jiangsu Chia Tai-Tianqing Pharmaceutical Co. 株式会社, Novartis International AG, ロシュ・ホールディングAG, Sanofi S.A., Taiho Pharmaceutical Co. 株式会社. .

データ中心のレポートは市場動向に焦点を当てています, セグメントの現状と見通し. さまざまな市場セグメントにわたる市場を包括的にカバー, レポートは既存のプレイヤーにとって貴重な資産です, 新規参入者と将来の投資家.

このレポートを購入する理由?
▹ Get a detailed picture of the China Oncology Drugs Market
▹ Identify segments/areas to invest in over the forecast period in the China Oncology Drugs Market
▹ 競争環境を理解する, 市場の主要企業
▹ Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
▹ 3ヶ月間の戦略コンサルティングとリサーチサポート.
▹ シングルユーザーライセンスに印刷認証を提供.